Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Acta Biomedica de l'Ateneo Parmense 2011-Apr

Clinical effectiveness of a highly standardized and bioavailable mixture of flavonoids and triterpenes in the management of acute hemorroidal crisis.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
Francesco Di Pierro
Giovanni Spinelli
Giovanni Monsù
Giorgio Alvisi
Giuseppe Bacci
Carla Baiocchi
Massimo Buratta
Angelo Martinoli
Franco Vitali
Carlo Agrifoglio

キーワード

概要

OBJECTIVE

Patients with acute haemorrhoidal crisis often need of an immediate and effective pharmacological approach to alleviate their pain, bleeding and swelling or have to be referred by the general practitioner to the surgeon for a definitive treatment. Effective and not invasive treatment control of the acute crisis could be of practical use in order to avoid or to delay invasive procedures to a time more convenient for the patient and/or for the surgeon.

METHODS

After enrolling, according to the group treatment, every patient starts taking 1 tablet every 8 hours for 7 days of Emospid or 2 tablets every 8 hours for 7 days of MMDH tablets. According to a simplified PATE 2000 classification, the following parameters were evaluated: haemorrhoidal grade, internal and external haemorrhoids, internal and external oedema, internal and external thrombosis, bleeding, bleeding intensity, pain, itching, defecation problems and urgency, tenesm, mucus in stools and sphinterial tone.

RESULTS

In the Emospid group, within the considered period, 35 patients out 40 shift downwards of 1 grade of the haemorrhoidal scale (from III to II and from II to I); 22 out of 29 stop bleeding; bleeding intensity drops by about 90%; pain ceased in 33 out of38; pain intensity drops by about 75%; itching ceased in 25 out 35; tenesm ceased in 32 out of 33; sphinterial tone reduced from hypertonic to normal in 19 out 24; mucus in the stools was found in 3 out of 12; 12 out 35 still presented defecation disorders; defecation urgency was found in 2 out of 14; need to defecate in 2 times was found in 1 out of 17; acute events (external and/or internal oedema, external and/or internal thrombosis) was found in 10 out of 36. In the MDHH group results were, in terms of global evaluation, inferior of about 25-50% according to the considered parameter when compared with the one got by the Emospid treatment.

CONCLUSIONS

Patients with acute haemorrhoidal crisis may be successfully treated with Emospid in order to avoid or to delay, if acute crisis relapsed, invasive procedures. Moreover, the treatment with Emospid shows to be more effective, if compared with MMDH, in counteracting acute haemorrhoidal crisis. (www.actabiomedica.it)

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge